The effect of i.v. L-NG methylarginine hydrochloride (L-NMMA: 546C88) on basal and acetazolamide (Diamox®) induced changes of blood velocity in cerebral arteries and regional cerebral blood flow in man

Cephalalgia

Volumn 25, Issue 5, 2005, Pages 344-352

  Lassen, Lisbeth Hjorth ^a,c   Sperling, B ^b   Andersen, A R ^a   Olesen, J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c NONE   (Denmark)

Author keywords

Acetazolamide; CBF; L NMMA; SPECT; TCD

Indexed keywords

ACETAZOLAMIDE; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE;

ADULT; ARTERIOLE; ARTICLE; BLOOD FLOW VELOCITY; BRAIN ARTERY; BRAIN BLOOD FLOW; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOPPLER ECHOGRAPHY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MIDDLE CEREBRAL ARTERY; NORMAL HUMAN; OPEN STUDY; OXIDATIVE STRESS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ACETAZOLAMIDE; ADULT; BLOOD FLOW VELOCITY; CEREBRAL ARTERIES; CEREBROVASCULAR CIRCULATION; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; OMEGA-N-METHYLARGININE; REGIONAL BLOOD FLOW;

EID: 17644363043     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2004.00862.x     Document Type: Article

References (38)

1. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43:109-41.
2. Lassen LH, Ashina M, Christiansen I, Ulrich V, Olesen J. Nitric oxide synthase inhibition in migraine. Lancet 1997; 349:401-2.
3. Nagayama M, Zhang F, Iadecola C. Delayed treatment with aminoguanidine decreases focal cerebral ischemic damage and enhanges neurologic recovery in rats. J Cereb Blood Flow Metab 1998; 18:1107-13.
4. O'Neil MJ, Murray TK, McCarty DR, Hicks CA, Dell CP, Patrick KE, et al. ARL 17477, a selective nitric oxide synthase inhibitor, with neuroprotective effects in animal models of global and focal cerebral ischaemia. Brain Res 2000; 871:234-44.
5. Alderton WK, Cooper CE, Knowles RG. Review article. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001; 357:593-615.
6. Iadecola C, Pelligrino DA, Moskowitz MA, Lassen NA. State of the art review. Nitric oxide synthase inhibition and cerebrovascular regulation. J Cereb Blood Flow Metab 1994; 14:175-92.
7. Kiss B, Dallinger S, Findl O, Rainer G, Eichler H-G, Schmetterer L. Acetazolamide-induced cerebral and ocular vasodilatation is independent of nitric oxide. Am J Physiol 1999; 276:1661-7.
8. White RP, Deane C, Vallance P, Markus HS. Nitric oxide synthase inhibition in humans reduces cerebral blood flow but not the hyperemic response to hyper capnia. Stroke 1998; 29:467-72.
9. Van Mil AHM, Spilt A, Van Buchem MA, Bollen ELEM, Teppema L, Westendorp RGJ, et al. Nitric oxide mediates hypoxia-induced cerebral vasodilatation in humans. J Appl Physiol 2002; 92:962-6.
10. White RP, Hindley C, Bloomfield PM, Cunningham VJ, Vallance P, Brooks DJ, et al. The effects of nitric Oxide synthase inhibitor L-NMMA on basal CBF and vasoneuronal coupling in man: a PET study. J Cereb Blood Flow Metab 1999; 19:673-8.
11. Olesen J, Thomsen LL, Lassen LH, Olesen IJ. The nitric oxide hypothesis of migraine and other vascular headaches. Cephalalgia 1995; 15:94-100.
12. Lauritzen M. Review article. Pathophysiology of the migraine aura. The spreading depression theory. Brain 1994; 117:199-210.
13. Olesen J, Friberg L, Olsen TS, Iversen HK, Lassen NA, Andersen AR, et al. Timing and tomography of cerebral blood flow, aura and headache during migraine attacks. Ann Neurol 1990; 28:791-8.
14. Celsis P, Goldman T, Henriksen L, Lassen NA. A method for calculating regional cerebral blood flow from emission computed tomography of inert gas concentrations. J Comput Assist Tomogr 1981; 5:641-5.
15. Holm S. Radiation doses with Xenon-133, xenon-127 and Tc99m HMPAO. In: Olesen J, editor. Migraine and Other Headaches: the Vascular Mechanisms. New York: Raven Press, 1991:43-6.
16. Sorteberg W. Cerebral artery blood velocity and cerebral blood flow. In: Newell DW, Aaslid R, editors. Transcranial Doppler. New York: Raven Press, 1992:57-67.
17. Dahl A, Russell D, Nyberg-Hansen R, Rootwelt K. Effect of nitroglycerin on cerebral circulation measured by transcranial doppler and SPECT. Stroke 1989; 20:1733-6.
18. Markwalder T-M, Grolimund P, Seiler RW, Roth F, Aaslid R. Dependency of blood flow velocity in the middle cerebral artery on end-tidal carbon dioxide partial pressure - A Transcranial Ultrasound Doppler Study. J Cereb Blood Flow Metab 1984; 4:368-72.
19. Joshi S, Young WL, Duong H, Ostapkovich ND, Aagaaard BD, Hashimoto T, Pile-Spellman J. Intracarotid infusion of the nitric oxide synthase inhibitor, L-NMMA, modestly decreases cerebral blood flow in human subjects. Anesthesiology 2000; 93:699-707.
20. Irikura K, Maynard KI, Moskowitz MA. Importance of nitric oxide synthase inhibition to the attenuated vascular responses induced by topical L-Nitroarginine during vibrissal stimulation. J Cereb Blood Flow Metab 1994; 14:45-8.
21. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from 1-arginine. Nature 1988; 333:664-6.
22. Micieli G, Bosone B, Costa A, Cavallini A, Marcheselli S, Pompeo F, et al. Opposite effects of 1-arginine and nitroglycerin on cerebral blood velocity: Nitric oxide precursors and cerebral blood velocity. J Neurol Sci 1997; 150:71-5.
23. Lassen NA. Cerebral blood flow and oxygen consumption in man. Physiol Rev 1959; 39:183-238.
24. Lassen LH, Iversen HK, Olesen JO. A dose-respose study of nitric oxide synthase inhibition in different vascular beds in man. Eur J Clin Pharmacol 2003; 59:499-505.
25. Lassen LH, Christiansen I, Iversen HK, Jansen-Olesen I, Olesen J. The effects of nitric oxide synthase inhibition on histamine induced headache and arterial dilatation in migraineurs. Cephalalgia 2003; 23:877-86.
26. Schmetterer L, Wolzt M, Grasilli U, Findl O, Strenn K, Simak S, et al. Nitric oxide synthase inhibition in the histamine headache model. Cephalalgia 1997; 17:175-82.
27. Adams RJ, Nichols FT, Hess DC. Normal values and physiological variables. In: Newell DW, Aaslid R, editors. Transcranial Doppler. New York: Raven Press, 1992:41-8.
28. Liu GT, Volpe NJ, Galetta SL. Pseudotumor cerebri and its treatment. Drugs Today 1998; 34:563-74.
29. Haan J, Sluis P, Ferrari M. Acetazolamide treatment for migraine aura status. Neurology 2000; 55:1588-9.
30. Vahedi K, Taupin P, Djomby R, El-Amrani M, Lutz G, Filipetti V, et al. Diamig investigators. Efficacy and tolerability of acetazolamide in migraine prophylaxis: a randomised placebo-controlled trial. J Neurol 2002; 249:206-11.
31. Severinghaus JW, Cotev S. Carbonic acidosis and cerebral vasodilation after diamox. Scand J Clin Lab Invest 1968; 102:I:E.
32. Bickler PE, Litt L, Banville DL, Severinghaus JW. Effects of acetazolamide on cerebral acid-base balance. J Appl Physiol 1988; 65:422-7.
33. 31P NMR study. J Cereb Blood Flow Metab 1989; 9:417-21.
34. 31P-NMR Study. Acta Physiol Scand 1988; 134:295-8.
35. Csete K, Barzó P, Bodosi M, Papp JG. Influence of nitrovasodilators and cyclooxygenase inhibitors on cerebral vasoreactivity in conscious rabbits. Eur J Pharmacol 2001; 412:301-9.
36. Wang Q, Poulson OB, Lassen NA. Effect of nitric oxide blockade by NG-nitro-L-arginine on cerebral blood flow response to changes in carbon dioxide tension. J Cereb Blood Flow Metab 1992; 12:947-53.
37. 2+/ calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem J 1992; 281:627-30.
38. Dahl A, Russell D, Rootwelt K, Nyberg-Hansen R, Kerty E. Cerebral vasoreactivity assessed with transcranial doppler and regional cerebral blood flow measurements. Dose, serum concentration, and time course of the response to acetazolamide. Stroke 1995; 26:2302-6.